The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 4
- 4 renewals
- Median first-year cost
- $999,934
- $3,989,313 in all
- Institutions
- 4
- 4 contact PIs
- Patents
- 5
- from 1 funded project
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- INTEGRATED SENSING SYSTEMS, INC. (ISSYS)1
- LYRA THERAPEUTICS, INC.1
- PULMOKINE, INC.1
- WINDTREE THERAPEUTICS, INC.1
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-B (F1))2
- Special Emphasis Panel (ZHL1 CSR-B (F2))2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2016 | Clinical study of aerosolized KL4 surfactant for neonatal RDS and BPD prevention2R44HL107000-03 | Segal, Robert | WINDTREE THERAPEUTICS, INC., PA | First-year cost $1,000,000 | Study section ZHL1 |
| FY2016 | Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis2R44HL132197-03 | Palasis, Maria | LYRA THERAPEUTICS, INC., MA | First-year cost $989,446 | Study section ZHL1 |
| FY2015 | An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension2R44HL102946-04 | Zisman, Lawrence S. | PULMOKINE, INC., NY | First-year cost $999,898 | Study section ZHL1 |
| FY2014 | Novel Micro-Implant to Measure Intracardiac Pressure in Congenital Heart Patients2R44HL110521-04 | Bocks, MartinNajafi, Nader | INTEGRATED SENSING SYSTEMS, INC. (ISSYS), MI | First-year cost $999,969 | Study section ZHL1 |
Patents from its funded projects
5 patents name 1 of the 4 funded projects.
- US 10,532,994 (opens the patent at USPTO, a PDF, in a new tab)NON-SELECTIVE KINASE INHIBITORSGranted January 14, 2020 to PULMOKINE, INC. and Gilead Sciences, Inc.R44HL102946 · PULMOKINE, INC., NY
- US 10,246,438 (opens the patent at USPTO, a PDF, in a new tab)NON-SELECTIVE KINASE INHIBITORSGranted April 2, 2019 to PULMOKINE, INC.R44HL102946 · PULMOKINE, INC., NY
- US 9,925,184 (opens the patent at USPTO, a PDF, in a new tab)SPRAY DRY FORMULATIONSGranted March 27, 2018 to PULMOKINE, INC. and Gilead Sciences, Inc.R44HL102946 · PULMOKINE, INC., NY
- US 9,815,815 (opens the patent at USPTO, a PDF, in a new tab)NON-SELECTIVE KINASE INHIBITORSGranted November 14, 2017 to PULMOKINE, INC. and Gilead Sciences, Inc.R44HL102946 · PULMOKINE, INC., NY
- US 8,889,104 (opens the patent at USPTO, a PDF, in a new tab)METHOD OF NEUTRALIZING AN AEROSOL CONTAINING A COMPOUND OF INTEREST DISSOLVED IN A LOW PH SOLUTIONGranted November 18, 2014R44HL102946 · PULMOKINE, INC., NY
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-15-0.3.4. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.